Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Litzow

Showing results (101-110 of 457) with videos related to

Pageof 46
Sort By:
Blood Cancer Journal|March 20, 2024
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplantAyalew Tefferi, Animesh Pardanani, Kebede H Begna, et al.
Best Practice & Research. Clinical Haematology|December 3, 2014
Improved accuracy of acute graft-versus-host disease staging among multiple centersJohn E Levine, William J Hogan, Andrew C Harris, et al.
Bone Marrow Transplantation|January 12, 2024
EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplantAnmol Baranwal, Abhishek Mangaonkar, Mithun V Shah, et al.
American Journal of Hematology|September 3, 2022
Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to ruxolitinibAyalew Tefferi, Animesh Pardanani, Kebede H Begna, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2017
Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host DiseaseFevzi F Yalniz, Mehrdad Hefazi, Kristen McCullough, et al.
American Journal of Hematology|March 6, 2013
The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazoleJason N Barreto, Cassidy L Beach, Robert C Wolf, et al.
Chest|January 12, 2021
Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell TransplantationZhenmei Zhang, Can Wang, Steve G Peters, et al.
Archives of Dermatology|October 19, 2005
Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantationMartha Q Lacy, William J Hogan, Morie A Gertz, et al.
Oncotarget|May 5, 2016
Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axisXiaojuan Yang, Jiuxia Pang, Na Shen, et al.
Leukemia & Lymphoma|March 31, 2009
Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myelomaLuciano J Costa, Shaji Kumar, Angela Dispenzieri, et al.
Pageof 46

Showing results (101-110 of 457) with videos related to

Sort By:
Pageof 46
Blood Cancer Journal|March 20, 2024
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplantAyalew Tefferi, Animesh Pardanani, Kebede H Begna, et al.
Best Practice & Research. Clinical Haematology|December 3, 2014
Improved accuracy of acute graft-versus-host disease staging among multiple centersJohn E Levine, William J Hogan, Andrew C Harris, et al.
Bone Marrow Transplantation|January 12, 2024
EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplantAnmol Baranwal, Abhishek Mangaonkar, Mithun V Shah, et al.
American Journal of Hematology|September 3, 2022
Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to ruxolitinibAyalew Tefferi, Animesh Pardanani, Kebede H Begna, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2017
Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host DiseaseFevzi F Yalniz, Mehrdad Hefazi, Kristen McCullough, et al.
American Journal of Hematology|March 6, 2013
The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazoleJason N Barreto, Cassidy L Beach, Robert C Wolf, et al.
Chest|January 12, 2021
Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell TransplantationZhenmei Zhang, Can Wang, Steve G Peters, et al.
Archives of Dermatology|October 19, 2005
Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantationMartha Q Lacy, William J Hogan, Morie A Gertz, et al.
Oncotarget|May 5, 2016
Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axisXiaojuan Yang, Jiuxia Pang, Na Shen, et al.
Leukemia & Lymphoma|March 31, 2009
Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myelomaLuciano J Costa, Shaji Kumar, Angela Dispenzieri, et al.
Pageof 46